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Magnetic study on biodistribution and
biodegradation of oral magnetic nanostructures in
the rat gastrointestinal tractQ1
MiguelQ2 Martín,a Alba Rodríguez-Nogales,b Víctor Garcés,a Natividad Gálvez,a
Lucía Gutiérrez,*c Julio Gálvez,b Deyanira Rondón,d Mónica Olivaresd and
Jose M. Dominguez-Vera*a
We have undertaken a magnetic study on the oral biodistribution and biodegradation of nude maghemite
nanoparticles of 10 nm average size (MNP) and probiotic bacteria, Lactobacillus fermentum, containing
thousands of these same nanoparticles (MNP–bacteria). Using AC magnetic susceptibility measurements
of the stomach, small intestine, cecum and large intestine obtained after rat sacrifice, and iron content
determination by ICP-OES, we have monitored the biodistribution and biodegradation of the maghemite
nanoparticles along the gastrointestinal tract, after oral administration of both MNP and MNP–bacteria.
The results revealed that the amount of magnetic nanoparticles accumulated in intestines is sensibly
higher when MNP–bacteria were administered, in comparison with MNP. This confirms our initial hypo-
thesis that the use of probiotic bacteria is a suitable strategy to assist the magnetic nanoparticles to over-
come the stomach medium, and to achieve their accumulation in intestines. This finding opens doors to
different applications. Since iron absorption in humans takes place precisely in the intestines, the use of
MNP–bacteria as an iron supplement is a definite possibility. We have actually illustrated how the adminis-
tration of MNP–bacteria to iron-deficient rats corrects the iron levels after two weeks of treatment.
Introduction
The unique magnetic properties of magnetite (Fe3O4)/maghe-
mite (γ-Fe2O3) iron oxide nanoparticles, their biodegradability
and low toxicity have paved the way for various biomedical
applications, including Magnetic Resonance Imaging (MRI),
drug delivery and magnetically induced therapeutic
hyperthermia.1–10 However, the efficiency of iron oxide nano-
particles as drugs requires the control of two crucial processes:
biodistribution and biodegradation. After their administration,
the iron oxide nanoparticles have, first, to specifically accumu-
late into the tissue to be imaged or treated, and secondly to be
degraded in an adequate manner and time to reduce potential
toxic effects.11
Most magnetite/maghemite nanoparticles reported for bio-
medical applications need to be administered by injection.
However, when the target is located at the gastrointestinal tract
(GI), oral drug administration is usually a more convenient
route, because it avoids the discomfort and additional pro-
cedures associated with intravenous delivery injections. Oral
delivery through organs in the gastrointestinal tract (GI) needs
to overcome a couple of important obstacles: the strong acidic
gastric environment that reduces drug stability, and the diges-
tive enzymes that degrade drugs, thus decreasing their bio-
availability. Data on biodistribution and biodegradation of
magnetic nanoparticles through the GI are currently still
scarce12 despite the opportunities that nanoparticles offer
nowadays in diagnosis and therapy of diseases in such an
area, such as intestines. Here is where the major diseases
develop, such as inflammatory bowel disease or colorectal
cancer, the third most common type of cancer, with 700 000
deaths in 2012.13
Furthermore, magnetite/maghemite nanoparticles have
emerged as new physical and chemical forms to control iron
deficiency. Iron has been recognized to be the micronutrient
with the largest deficiencies worldwide. Anemia is actually a
major global public health problem, affecting 20% of the
world’s population.14
Iron-deficiency anemia is caused by insufficient dietary
intake and absorption of iron. To increase daily iron intake,
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numerous supplements based on different classical chemical
iron forms are commercially available. It is well known that
the limitations of these iron supplements are their low bio-
availability and gastrointestinal side effects.15 Iron oxide nano-
particles have emerged as a promising route for iron
supplements since they are more bioactive than classical
chemical forms and have a much greater access to tissues.
Iron absorption takes place at the small intestine, preferen-
tially in the duodenum. It is therefore still a challenge to
develop routes for overcoming the strong acidic gastric
environment of the stomach and drive the iron nanoparticles
to the intestines. Parallel to this development, it is necessary
to gain more insights about the processes of distribution and
degradation of magnetic nanoparticles along the GI. Two
approaches can be envisaged to succeed in overcoming this
challenge: the use of magnetic nanoparticles with protective
coatings for avoiding the chemical attack at the stomach or the
use of bioplatforms as carriers towards the intestines. In this
regard, we have recently reported how probiotic bacteria, Lacto-
bacillus fermentum or Bifidobacterium breve, serve as platforms
to densely arrange magnetic nanoparticles on their external
surfaces.16 This is a promising route to allow the magnetic
nanoparticles to pass through the stomach medium and reach
the intestines, since probiotic bacteria constitute an important
part of natural microbiota, which survive the stomach con-
ditions and nest in different areas of intestines.
In this paper, we describe a magnetic study in parallel to
monitor the biodistribution and biodegradation of nude
10 nm maghemite nanoparticles (MNP) and probiotic bacteria
containing thousands of these same nanoparticles (MNP–
bacteria), over the bowel system after oral administration in
rats. The aim of this study is to compare the biodistribution
and biodegradation patterns of maghemite nanoparticles
when administered orally as single nanoparticles (MNP) or
aggregated onto a bioplatform, such as Lactobacillus fermentum
(MNP–bacteria).
To achieve this objective, we used AC magnetic suscepti-
bility measurements (the in- and out-of-phase susceptibility,
χ′(T ) and χ″(T ) respectively) of different tissues obtained after
rat sacrifice. In particular, we extracted the stomach, small
intestine, large intestine and cecum. The temperature depen-
dence of the out-of-phase susceptibility (χ″(T )) is a high-sensi-
tive parameter for the detection of magnetic nanoparticles in
tissues17,18 because: (i) other paramagnetic iron species
present in enterocytes do not contribute to χ″(T ); (ii) the
maghemite nanoparticle objects of this study are distin-
guished from other superparamagnetic native species present
in enterocytes such as ferritin, based on their blocking temp-
eratures, which serve as fingerprints for the identification of
the presence of these nanoparticles in tissue samples; (iii) the
maxima in χ′(T ) and χ″(T ) susceptibility curves give infor-
mation on particle size and degree of aggregation and (iv) AC
magnetic susceptibility of the administered nanoparticles per
mass of iron, provides a calibration curve for the quantitative
determination of the presence of the particles in tissue
samples.
Materials and methods
MNP and MNP–bacteria preparation
MNP and MNP–bacteria were prepared following a previously
described procedure.16,18 MNP were synthesized according to
Massart’s method by co-precipitation of Fe(II) and Fe(III) salts
in a stoichiometry of 0.5.18 By adjusting the pH to 11 with 3 M
NaOH and ionic strength with 1 M NaNO3, the average size of
the resulting magnetite nanoparticles is 10 nm. After oxidation
of magnetite to maghemite with 1 M HClO4, a colloid of
maghemite nanoparticles stable at pH 2 was obtained.20
For the preparation of MNP–bacteria, a liquid culture of
probiotic Lactobacillus fermentum CECT5716 was grown in a
common bacterial growth medium such as MRS at 37 °C with
orbital agitation for 24 h. Bacteria were centrifuged at 3000g
for 5 min and washed with distilled water. Then, an acid solu-
tion (pH 2) of MNP (66.6 μL, 0.95 M) was added to the bacteria
in an ice bath and mixed. The solution was diluted to 1 mL
with distilled water. Bacteria labelled with maghemite nano-
particles (MNP–bacteria) were collected at 100g, 20 min.
MNP and MNP–bacteria characterization was carried out by
Transmission Electron Microscopy (TEM) as previously reported.16
Animals
This study was carried out in accordance with the ‘Guide for
the Care and Use of Laboratory Animals’ as promulgated by
the National Institute of Health and the protocols approved by
the Ethics Committee of Laboratory Animals of the University
of Granada (Spain) (ref. no. CEEA-2010-286). All studies invol-
ving animals are reported in accordance with the ARRIVE
guidelines for reporting experiments involving animals.21,22
Male Wistar rats (180–200 g) obtained from Janvier
(St Berthevin Cedex, France) were housed individually in Mak-
rolon cages, maintained in an air-conditioned atmosphere
with a 12 h light–dark cycle, and provided with free access to
tap water and food ad libitum. They were randomly assigned to
different experimental groups (n = 4). One of them received
only the standard diet, whereas the three remaining groups
were fed an iron deficient diet (TD.80396) provided by Harlan
Laboratories (Madison, WI, USA). Two rats of this group
received a supplement of iron (1 mg per day per animal) by
suspensions of MNP or MNP–bacteria. All samples were
administered daily by oral gavage. Food and water intake was
recorded daily for all groups. Rat body weight was measured
twice a week. No significant differences were observed in
animal weight among the groups throughout the experiment.
Blood samples were taken after two weeks from the hepatic
portal vein in a heparinized tube to analyze the blood picture.
Then, the rats were sacrificed and the stomach, small intes-
tines, cecum and large intestines were collected, weighed and
immediately frozen in liquid nitrogen and stored at −80 °C.
Elemental analysis
Freeze-dried tissue samples together with MNP–bacteria and
MNP were weighed and acid digested for elemental analysis by
adding 65% HNO3 (w/v) and heating up to 95 °C for 1 h using
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a hot block. After that, the samples were allowed to cool down
to room temperature and 30% H2O2 (w/v) was added and
heated up to 95 °C for 1 h. Inductively coupled Plasma Optical
Emission Spectroscopy (ICP-OES) in a Perkin Elmer Optima
2100 DV was used to determine the iron concentration.
Agar dilutions
To evaluate the influence of dipolar interactions on the par-
ticle magnetic properties dilutions in 2% w/v agar of the MNP
and MNP–bacteria were prepared. MNP and MNP–bacteria
were mixed with liquid agar solution (at about 90 °C). The
mixture was then quickly placed in a warm ultrasonic bath
that allowed the slow jellification of the agar while the
materials were dispersed by the ultrasound. The resulting gels
were freeze-dried for 24 h in a Telstar lyoquest lyophilizer.
Magnetic characterization
Tissue samples, MNP–bacteria and MNP were freeze-dried and
the corresponding powders were placed in gelatine capsules
for magnetic characterization. Measurements were performed
in a Quantum Design MPMS-XL SQUID magnetometer
equipped with an AC (alternating current) magnetic suscepti-
bility option. AC susceptibility measurements were performed
with an AC amplitude of 0.41 Oe, in the temperature range
between 10 and 300 K and at a frequency of 11 Hz.
Dipolar interactions were checked by calculating the para-
meter τ0, which is the pre-exponential factor from the Arrhe-
nius equation for the relaxation time, τ = τ0 exp(Ea/kBT ), where
kB is the Boltzmann constant and Ea the single particle an-
isotropy energy barrier. Calculations were performed in
selected samples only when the experimental noise was low
enough to perform an accurate data fit. This analysis is based
on the complementarity of the relaxational information con-
tained in the in-phase and out-of-phase magnetic suscepti-
bility data and has been previously described.23
Results and discussion
TEM analysis of MNP and MNP–bacteria
TEM images of MNP mainly showed irregular spherical nano-
particles (Fig. 1). The mean particle size was 10.0 nm (σ = 0.9).
For MNP–bacteria, large accumulations of nanoparticles were
seen by TEM at the external surfaces of the bacteria (Fig. 1).
Only a small fraction of nanoparticles is in the inter-bacterial
region, while inside the bacteria, nanoparticles are hardy
observable. The MNP adhere to the bacterial external surface,
probably at the EPS, due to the electrostatic interaction
between positive MNP and negative bacterial EPS.16
Fe analysis of tissues
Iron contents in every gastrointestinal tissue of rat controls
and rats administered with MNP and MNP–bacteria were
measured by ICP-OES. As shown in Fig. 2, the total amount of
iron in intestines (the addition of the iron content in cecum,
small and large intestines) is sensibly higher when adminis-
tered with MNP–bacteria (0.620 mg Fe per g tissue) than with
MNP (0.414 mg Fe per g tissue). The difference is particularly
significant in the cecum, where the amount of iron after
administration of MNP–bacteria (0.384 mg Fe per g tissue) is
twice that obtained after administration of MNP (0.203 mg Fe
per g tissue). This finding is in agreement with the known fact
that probiotic bacteria preferentially nest in the different areas
of the GI, and suggests that the probiotic bacteria act as a
useful carrier to assist the magnetic nanoparticles in over-
coming the stomach medium.
Magnetic study of tissues
The magnetic properties of MNP and MNP–bacteria were
characterized by AC magnetic susceptibility. The in-phase sus-
ceptibility of both samples show a single maximum
accompanied by a maximum at slightly lower temperatures for
the out-of-phase component, indicative of the magnetic relax-
ation phenomenon of magnetic blocking of superpara-
magnetic particles (Fig. 3). The out-of-phase susceptibility
becomes zero above 250 K, indicating that these samples are
superparamagnetic above these temperatures. Slight differ-
ences are observed between the two samples regarding the
temperature position of the maxima. Specifically, χ′(T ) maxima
were located at ∼160 and ∼200 K for MNP and MNP–bacteria
Fig. 1 A typical TEM micrograph (left) of maghemite nanoparticles
(MNP). On the right, a micrograph of a thin epoxy resin section showing
the presence of particles at the external surface of bacteria (MNP–
bacteria).
Fig. 2 Iron content in bowel tissues after MNP and MNP–bacteria
administration. Black bar: rat controls; red bar: rats administered with
MNP and blue bar: rats administered with MNP–bacteria. Error bars,
±sem.
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respectively. This behaviour is in agreement with the expected
variations in the dipolar magnetic interactions among nano-
particles produced by different degrees of aggregation when
comparing isolated (MNP) or grafted to the external bacterial
surface (MNP–bacteria).16,17
Further analysis of the interparticle interactions has been
performed through the characterization of the same materials
diluted in agar to try to reduce the interparticle interactions
(Fig. 4). It can be observed that the dilution in agar results in a
shift towards lower temperatures of the χ″(T ) maximum only
for the MNP, but not for the MNP–bacteria. This fact is easily
understood given that the agar dilution of MNP–bacteria
reduces the distance between bacteria but keeps the interparti-
cle distances unchanged, as they remain on the bacteria
surface. However in the case of the MNP, the χ″(T ) maximum
shifts from 140 K for the concentrated sample to around 60 K
for the diluted one (Fig. 4) as a consequence of the higher
interparticle distances.
The importance of the interparticle interactions has also
been evaluated through the determination of the pre-exponen-
tial factor, τ0 of the Arrhenius equation. In this case, τ0 for the
original MNP and MNP–bacteria present values outside the
negligible dipolar interaction range (10−9–10−12 s) being
around 10−24 and 10−21 s respectively. However, the dilution of
MNP in agar served to reduce the interparticle interactions, as
this sample presents a τ0 value of 1.6 × 10
−12 s, located within
the negligible interaction limit.
The χ′ and χ″ profiles of the different organs are close to
those of administered materials, as all of them show a single
in-phase and out-of-phase maxima (Fig. 5). Interestingly, two
different features stand out. First, the location in temperature
of the χ″ maximum from both cecum samples is located at sig-
nificantly lower temperatures (below 50 K) than the rest of the
tissues, with maxima located between 100 and 150 K (Table 1).
The location at lower temperatures indicates a transformation
of the administered particles that could be associated with a
reduction of the particle size, a reduction of the interparticle
interactions, or both. The second interesting feature appears
in the cecum sample from the animal that received the MNP
treatment, where a paramagnetic tail is observed in χ′(T ) at low
temperatures, indicative of the presence of non-mineral iron
species.
It is also worth mentioning that the height of the out-of-
phase susceptibility maxima may be used as a surrogate of the
iron concentration in the form of a given species.23 In this
study, in animals from both treatments, both the large and
small intestines present a similar concentration of iron mag-
netic nanoparticles while the stomach seems to be the organ
Fig. 3 Temperature dependence of the in-phase and out-of-phase
magnetic susceptibility of MNP (circles) and MNP–bacteria (triangles)
per mass of sample.
Fig. 4 Temperature dependence of the out-of-phase magnetic sus-
ceptibility of MNP and MNP–bacteria (black) and their corresponding
dilutions in agar (white) scaled to their maximum.
Fig. 5 Temperature dependence of the in-phase and out-of-phase
magnetic susceptibility per mass of tissue for different organs from the
rats treated with MNP (right) and MNP–bacteria (left).
Table 1 Temperature maxima of χ’(T ) and χ’’(T ) curves after MNP or
MNP–bacterial treatment for different tissues
Tissue
Temperature (K) of χ′ and χ″ maxima
MNP MNP–bacteria
χ′ χ″ χ′ χ″
Stomach 180 ≈140 180 ≈140
Small intestine 180 ≈140 180 ≈140
Large intestine 180 ≈130 160–180 ≈140
Cecum 50–100 30–50 70–100 <50
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with a smaller amount of particles and the cecum the organ
that accumulates the biggest amount.
Using the magnetic susceptibility data we can quantify the
iron concentration in the form of nanoparticles in every tissue
following the protocols described elsewhere (Fig. 6).17,24 This
quantitative determination of iron can be performed given the
existence of standards, in this case MNP and MNP–bacteria,
with the same magnetic behaviour as observed in most of the
tissue samples. Although we can quantify with a relatively low
error the iron content in the stomach, small and large intes-
tines, this is not possible in the cecum, due to the different
temperature locations of the maximum observed in this tissue
when compared with the administered materials. For this
organ, the determination of mg of Fe nanoparticles per g of
dry tissue is therefore not as rigorous as for the other tissues.
The first conclusion drawn from these data is that the
amount of magnetic nanoparticles in intestine tissues (small,
large and cecum) is higher after administration of MNP–
bacteria than MNP. As in the iron content analysis by ICP-OES,
the difference is particularly significant in the cecum, where
the values of the out-of-phase magnetic susceptibility are five
times higher. The only tissue where nanoparticle accumulation
is higher when administrating MNP than MNP–bacteria is
precisely the stomach, 0.027 against 0.018 mg g−1 stomach for
MNP and MNP–bacteria respectively, which is another piece
of evidence that bacteria act as a useful carrier to assist the
magnetic nanoparticles in overcoming the stomach medium
and reaching the intestines.
From a qualitative point of view, the pattern of biodistribu-
tion of maghemite nanoparticles after ingestion of MNP and
MNP–bacteria seems similar at first sight: nanoparticles distri-
bute along the GI and specifically accumulate in the cecum.
However, in a deeper analysis, some drastic differences are
noted. First, the accumulation of magnetic nanoparticles in
the cecum is more specific when MNP–bacteria were adminis-
tered, since the values of χ″(T ) for the cecum is ten times
larger than for other tissues, whereas this difference is only
double when MNP were administered. Second, the maxima of
χ″(T ) in the cecum (around 50 and 30 K after administration of
MNP–bacteria and MNP, respectively) are located at lower
temperatures with respect to the original MNP or MNP-
bacteria samples (200 and 160 K, respectively), and are also below
the MNP sample diluted in agar, which presents negligible
interactions. This fact points out the existence of a degradation
process of magnetic nanoparticles. The fact that the out-of
phase susceptibility maxima is below the non-interaction limit
determined by the τ0 value for the MNP agar dilution, indi-
cates that in addition to a disaggregation process of the MNP
and maybe a release of particles from the MNP–bacteria, a
reduction of the particle size as a consequence of the biodegra-
dation process also occurs. The reduction of the particle size
would result in a release of free iron atoms, a fact that agrees
with the paramagnetic tail observed in χ′(T ) at low tempera-
tures in the cecum sample from the animals that received the
MNP treatment and that has been previously observed in MNP
samples degraded artificially.18 In contrast, the absence of a
paramagnetic tail in the cecum χ′(T ) curve after MNP–bacteria
administration points to the existence of a higher accumu-
lation of less-degraded magnetic nanoparticles.
These same conclusions can also be drawn from comparing
the ratios between iron concentrations from maghemite nano-
particles (estimated by SQUID measurements) and total iron
(measured by ICP-OES), in every tissue, after MNP or MNP–
bacteria administration (Table 2). This ratio is bigger at the
stomach for MNP, meaning that maghemite nanoparticles
accumulate more in this organ when administered with MNP
than with MNP–bacteria. In contrast, the intestines present
bigger ratios for the MNP–bacteria treatment, this difference
being significantly higher for the cecum, where the MNP may
have degraded faster or accumulated in a lower amount than
the MNP–bacteria.
Table 2 Comparison of total iron contents (mg Fe per g sample) in
bowel tissues (measured by ICP-OES) and iron as maghemite nano-








Stomach Control 0.00 0.05 0.00
MNP 0.03 0.09 0.33
MNP–bact 0.02 0.08 0.25
Small
intestine
Control 0.00 0.06 0.00
MNP 0.03 0.07 0.43
MNP–bact 0.04 0.08 0.50
Large
intestine
Control 0.00 0.07 0.00
MNP 0.03 0.06 0.50
MNP–bact 0.04 0.07 0.60
Cecum Control 0.00 0.13 0.00
MNP 0.06 0.20 0.30
MNP–bact 0.30 0.40 0.75
Fig. 6 Iron concentration, in the form of magnetic nanoparticles, in
every tissue, calculated from the magnetic measurements. Error bars,
±sem.
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In view of these findings and taking into account that nano-
particles passes through the GI tract following the order:
stomach, small intestine, cecum and finally large intestine, it
is an interestingfact that the maxima in the χ′(T ) and χ″(T )
curves are located at lower temperatures in the cecum than in
the following tissue (large intestine). It could be postulated
that a small fraction of the MNP and MNP bacteria pass
through the whole GI and is probably excreted through the
feces, while most of it, especially MNP–bacteria, overcome the
stomach medium and accumulate in the cecum.
Since iron absorption takes place in the small intestine,
especially the duodenum, iron supplements must pass through
the stomach and reach the small intestine. Our findings show
that the concentration of maghemite nanoparticles at the
small intestine is higher when administered with MNP–
bacteria than with MNP. Accordingly this MNP–bacteria
should be more effective for iron supply than MNP. To confirm
this, iron plasma and haemoglobin levels were measured in
four groups of rats: healthy, iron-deficient and iron-deficient
rats after administration of MNP or MNP–bacteria. Results pre-
sented in Fig. 7 show improvement in iron status after treat-
ment with MNP–bacteria. In fact, both iron plasma and
haemoglobin levels were corrected to healthy values in rats fed
MNP–bacteria over two weeks, while those under treatment
with MNP failed to reach normal values after the same period.
Conclusions
The collective analysis of iron contents and magnetic suscepti-
bilities of the different GI tissues (stomach, small and large
intestines and cecum) reveals different biodistribution and
biodegradation patterns of the maghemite nanoparticles after
their ingestion as simple MNP or as MNP–bacteria entities.
The results confirm that the use of probiotic bacteria is a suit-
able strategy to assist the magnetic nanoparticles to overcome
the stomach medium for achieving their accumulation in
intestines, especially in the cecum. We believe that these find-
ings have a wide applicability in biodistribution and biodegra-
dation studies involving oral magnetic nanostructures and
establish a framework for their applications in medicine. As an
example of this, we have illustrated how the administration of
MNP–bacteria to iron-deficient rats corrects the iron levels
after two weeks of treatment.
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